- AI-screener
- Securities US
- Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
$6.260
$0.090
1.45%
18 Jun 20:00
$4.020
$15.100
52 weeks low/high
Market sentiment
Section about market participants' moods: bulls holding long positions (“longs”) and bears holding short positions (“shorts”).
Overall assessment
bearish sentiment increases
2day with a yield of-0.32%
Long
100.00%Short
0.00%| Index | Bulls | Bears |
|---|---|---|
Confidence | — | |
Support | — | |
Cash flows | — |
Technical analysis
- Trend ClassFlat and Down
- PatternChannel
- EMA-20Bearish reversalThe price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.
- EMA-50Bullish reversal2025-05-16 the price crossed up the moving average line and getting closer to the MA, which means that the upside trend weakens.
- EMA-100Bearish reversal2025-06-13 the price crossed down the moving average line and formed a short-term downside trend.
- StochasticBearishThe stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: signal line crossed the middle level.
- RSIBullish weakeningRSI indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: entrance to the overbought zone.
- MACDBullish weakeningOscillator MACD is in the positive territory it's lower than the signal line and falls. These factors mean that the growing period is over. Last signal: main and signal line crossing.
- Candle pattern typeDojiIs formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | 1.79% | 0.50% | $6.040 | $6.470 | 4.35M |
| Week | -5.01% | 1.16% | $6.040 | $6.725 | 19.26M |
| Month | -2.95% | 2.96% | $6.010 | $7.020 | 113.78M |
| 3 Months | 9.82% | 2.67% | $4.020 | $7.020 | 324.69M |
| 6 Months | -24.76% | 14.08% | $4.020 | $11.980 | 727.23M |
| Year | 5.74% | 0.64% | $4.020 | $15.100 | 2.84B |
| 3 years | -77.28% | 66.05% | $1.420 | $36.140 | 7.38B |
| 5 years | -91.12% | 112.97% | $1.420 | $137.610 | 21.86B |
| All time | -21.56% | 79.48% | $1.420 | $137.610 | 23.26B |
Volatility
| EBS | By industry | |
|---|---|---|
| Yesterday | 2.24% | 0.93% |
| Week | 7.17% | 5.55% |
| Month | 22.14% | 12.78% |
| 3 Months | 87.90% | 22.23% |
| 6 Months | 101.34% | 29.80% |
| Year | 121.21% | 38.84% |
| 3 years | 203.77% | 82.02% |
| 5 years | 220.79% | 115.22% |
| All time | — | — |
- Sortino
- 0.03
- Sharpe
- 0.03
- Sterling
- 0.05
- Liquidity index
- 5.05
- Alpha
- -0.00474
- Beta
- 1.71
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$337.61M
Capitalization
54.28M
Shares outstanding
Health Care
Sector
Biotechnology
Industry
Mr. Robert G. Kramer Sr.
CEO
Website
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.